Zymeworks Share Holder Equity 2016-2022 | ZYME

Zymeworks share holder equity from 2016 to 2022. Share holder equity can be defined as the sum of preferred and common equity items
Zymeworks Annual Share Holder Equity
(Millions of US $)
2021 $249
2020 $410
2019 $246
2018 $180
2017 $116
2016 $68
2015 $18
Zymeworks Quarterly Share Holder Equity
(Millions of US $)
2022-06-30 $222
2022-03-31 $282
2021-12-31 $249
2021-09-30 $279
2021-06-30 $321
2021-03-31 $377
2020-12-31 $410
2020-09-30 $432
2020-06-30 $491
2020-03-31 $522
2019-12-31 $246
2019-09-30 $310
2019-06-30 $334
2019-03-31 $170
2018-12-31 $180
2018-09-30 $170
2018-06-30 $186
2018-03-31 $95
2017-12-31 $116
2017-09-30 $83
2017-06-30 $97
2017-03-31 $50
2016-12-31 $68
2016-09-30 $0
2016-06-30 $0
2016-03-31 $0
2015-12-31 $18
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.390B $0.027B
Zymeworks Inc. is a clinical-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The companys lead product candidate includes ZW25 and ZW33 which are in clinical trial stage. Zymeworks Inc. is headquartered in Vancouver, Canada.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $160.059B 9.71
GSK (GSK) United Kingdom $81.408B 9.78
Bio-Rad Laboratories (BIO.B) United States $15.412B 34.05
QIAGEN (QGEN) Netherlands $11.018B 18.45
Biohaven Pharmaceutical Holding (BHVN) United States $10.535B 0.00
Ginkgo Bioworks Holdings (DNA) United States $5.561B 0.00
Arcus Biosciences (RCUS) United States $1.821B 35.53
Myovant Sciences (MYOV) United Kingdom $1.600B 0.00
Emergent Biosolutions (EBS) United States $1.482B 8.59
Enzo Biochem (ENZ) United States $0.120B 0.00
Gelesis Holdings (GLS) United States $0.104B 0.00
SQZ Biotechnologies (SQZ) United States $0.097B 0.00
Ambrx Biopharma (AMAM) United States $0.089B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00